HOUSTON, Oct. 24, 2017 /PRNewswire/ -- RadiaDyne announces it received notice of additional FDA clearance for two new Indications
ABOUT OARTRAC: OARtrac® is a transformational, patented, patient monitoring technology which monitors the delivery of clinical radiation dose for cancer treatment in real-time. For decades, Physicians have desired to physically verify the actual in-vivo dose delivered during treatment to the targeted cancer tumor site and surrounding healthy tissue. The OARtrac® system can provide diagnostic pinpoint accuracy measurement of the radiation treatment plan by verifying the dose delivered is consistent with the prescribed dose. Furthermore, based on reviewing the accumulative dose data provided by the system, Radiation Oncologists can adjust subsequent treatment if required allowing for a true adaptive radiation therapy protocol.
ABOUT RADIADYNE: RadiaDyne is a privately held medical device and patient monitoring technology leader focused on improving cancer treatment outcomes. RadiaDyne designs and innovates specialized technology and treatment devices which assist Radiation Oncologists in delivering radiation dose to the cancerous targets while minimizing damage to the surrounding healthy tissue. RadiaDyne is the pioneer in developing and offering real-time clinical dose monitoring systems through their patented innovative OARtrac® system.
Please visit our LinkedIn page for the latest technology updates, and email [email protected] for questions and comments. Visit www.RadiaDyne.com for more information.
View original content:http://www.prnewswire.com/news-releases/radiadyne-receives-clearance-for-two-additional-fda-indications-for-the-oartrac-system-300542253.html
Subscribe to our Free Newsletters!
Strokes occur when blood flow to an area of the brain is cut off. It is imperitive to detect the ...View All